Pub Date : 2021-07-08DOI: 10.15406/jccr.2021.14.00519
G. Fazio, taffiere Elio, L. Gianturco, L. D. Diodoro, S. Pipitone, Emanuele Verghi, P. Colonna, M. Volterrani, Gabriele Catena
{"title":"Anticoagulation with Edoxaban in COVID-19 patients","authors":"G. Fazio, taffiere Elio, L. Gianturco, L. D. Diodoro, S. Pipitone, Emanuele Verghi, P. Colonna, M. Volterrani, Gabriele Catena","doi":"10.15406/jccr.2021.14.00519","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00519","url":null,"abstract":"","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85609568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-06DOI: 10.15406/jccr.2021.14.00516
G. Fazio, Randazzo Natale Eliseo
The technical possibility to diagnosis of Atrial Fibrillation is progressive ameliorate, and the number of asymptomatic patients affected by Atrial Fibrillation is increasing. For long time the ECG performed in patient with palpitation or stroke was the unique possibility to obtain a diagnosis of atrial fibrillation. For this reason a secondary Stroke was frequently in previously asymptomatic patients. A lot of patients that we consider “Asymptomatic patients” were been recognized only by cardiac Holler. exam unfrequently were present short episodes of atrial fibrillation. increased to 84%.
{"title":"New devices for diagnosis of atrial fibrillation: is necessary to treat with oral anticoagulation all patients?","authors":"G. Fazio, Randazzo Natale Eliseo","doi":"10.15406/jccr.2021.14.00516","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00516","url":null,"abstract":"The technical possibility to diagnosis of Atrial Fibrillation is progressive ameliorate, and the number of asymptomatic patients affected by Atrial Fibrillation is increasing. For long time the ECG performed in patient with palpitation or stroke was the unique possibility to obtain a diagnosis of atrial fibrillation. For this reason a secondary Stroke was frequently in previously asymptomatic patients. A lot of patients that we consider “Asymptomatic patients” were been recognized only by cardiac Holler. exam unfrequently were present short episodes of atrial fibrillation. increased to 84%.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85382464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-28DOI: 10.15406/jccr.2021.14.00513
O. Centurión
The utilization of targeted genetic abnormalities to personalize AF therapy is a compelling approach in current era of efforts to individualize the best therapeutic option for a certain patient. There are certain advantages and disadvantages in the implementation of gene therapy for AF.10–12 Some advantages comprise the fact that is tissue specific with fewer side effects. Due to the fact that the AF substrate is not homogeneous, the efficacy of a single genetic alteration may decrease, and it may preclude the simplicity of the procedure.
{"title":"Role of microRNA in atrial fibrillation: What are the implications for gene therapy?","authors":"O. Centurión","doi":"10.15406/jccr.2021.14.00513","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00513","url":null,"abstract":"The utilization of targeted genetic abnormalities to personalize AF therapy is a compelling approach in current era of efforts to individualize the best therapeutic option for a certain patient. There are certain advantages and disadvantages in the implementation of gene therapy for AF.10–12 Some advantages comprise the fact that is tissue specific with fewer side effects. Due to the fact that the AF substrate is not homogeneous, the efficacy of a single genetic alteration may decrease, and it may preclude the simplicity of the procedure.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77772529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-24DOI: 10.15406/jccr.2021.14.00512
R. G. Gandhi, L. Boppana, Sravani Lokineni, Megha Garg
Back pain is one of the most common reasons for outpatient visits but is rarely severe enough to require hospitalization. Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, a chronic inflammatory disorder is one of the rare causes of back pain which occurs in combination with skin symptoms. Here, we present a case of SAPHO syndrome in a 39-year-old man who presented with osteoarticular and dermatologic manifestations.
{"title":"A rare case of back pain: sapho syndrome","authors":"R. G. Gandhi, L. Boppana, Sravani Lokineni, Megha Garg","doi":"10.15406/jccr.2021.14.00512","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00512","url":null,"abstract":"Back pain is one of the most common reasons for outpatient visits but is rarely severe enough to require hospitalization. Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, a chronic inflammatory disorder is one of the rare causes of back pain which occurs in combination with skin symptoms. Here, we present a case of SAPHO syndrome in a 39-year-old man who presented with osteoarticular and dermatologic manifestations.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85739357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
homocysteine levels, transglutaminase antibodies, prothrombin and partial prothrombin levels were within normal ranges, and the prothrombin gene variant G20210 and Factor V Leiden mutations were not detected.
{"title":"Low burden atrial fibrillation and iron deficiency anemia as a contributing factor of thromboembolic events","authors":"Vassilara Foula, Papadopoulos Ioannis, Pipilis Athanasios, Plomaritoglou Androniki, Pothitos George, Spiridaki Aikaterini","doi":"10.15406/jccr.2021.14.00511","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00511","url":null,"abstract":"homocysteine levels, transglutaminase antibodies, prothrombin and partial prothrombin levels were within normal ranges, and the prothrombin gene variant G20210 and Factor V Leiden mutations were not detected.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78309404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-20DOI: 10.15406/jccr.2021.14.00509
F. Cacciapuoti, Fulvio Cacciapuoti
S-adenosyl-methionine; methyl group; S-adenosyl-homocysteine; S-adenosyl homocysteine Abstract Increased levels of homocysteine (HHcy) can induce both systolic and diastolic left ventricular (LV) dysfunction that may evolve until chronic heart failure (HF). It is known that HHcy acts as an independent risk factor for atherosclerosis and hypercoagulation. This condition may cause coronary artery disease (CAD. Chronic reduction of oxygen supply to the myocardium can induce a reduction in LV contractility. These conditions can further evolve towards HF with reduced ejection fraction (HFrEF). But, HHcy can be also responsible for adverse cardiac remodeling for accumulation and proliferation of interstitial collagen, increased fibrosis and myocardial stiffness and preserved LV ejection fraction (HFpEF). Both HF can be further favoured by the advanced age, hypertension, diabetes and others. The administration of some nutrients, such as folic acid and B 12 vitamin can delay or avoid these cardiac complications. However, the cellular mechanisms behind the adverse effects of Hcy on cardiac remodeling and pump function are not understood.
{"title":"Heart failure in patients with high homocysteine levels","authors":"F. Cacciapuoti, Fulvio Cacciapuoti","doi":"10.15406/jccr.2021.14.00509","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00509","url":null,"abstract":"S-adenosyl-methionine; methyl group; S-adenosyl-homocysteine; S-adenosyl homocysteine Abstract Increased levels of homocysteine (HHcy) can induce both systolic and diastolic left ventricular (LV) dysfunction that may evolve until chronic heart failure (HF). It is known that HHcy acts as an independent risk factor for atherosclerosis and hypercoagulation. This condition may cause coronary artery disease (CAD. Chronic reduction of oxygen supply to the myocardium can induce a reduction in LV contractility. These conditions can further evolve towards HF with reduced ejection fraction (HFrEF). But, HHcy can be also responsible for adverse cardiac remodeling for accumulation and proliferation of interstitial collagen, increased fibrosis and myocardial stiffness and preserved LV ejection fraction (HFpEF). Both HF can be further favoured by the advanced age, hypertension, diabetes and others. The administration of some nutrients, such as folic acid and B 12 vitamin can delay or avoid these cardiac complications. However, the cellular mechanisms behind the adverse effects of Hcy on cardiac remodeling and pump function are not understood.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81550398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-03DOI: 10.15406/jccr.2021.14.00508
T. L. Martinez, Sidney Carvalho Fernandes, A. Saldanha, A. Margeotto, A. Gasparoto, J. Aldrighi, Marco Antonio De Vivo Barros
Many research groups on atherosclerosis have sought through prospective large-scale epidemiological studies to better understand which residual factors would be associated with cardiovascular risk. Thus, atherogenic dyslipidemia was defined, such as the presence in an individual of decreased HDL-C levels, increased triglyceride levels, and a relatively high proportion of small and dense LDL-C particles. On the other hand, it was found that atherogenic dyslipidemia is present in cases of insulin resistance and metabolic syndrome (low HDL-C and elevated triglycerides are part of the definition of this syndrome) and consequently in patients with type 2 diabetes mellitus. Regarding treatment, there are studies in diabetic patients with risk reduction with fenofibrate, and the guidelines recommend the association of fenofibrate with statins. Diabetes mellitus is also an important cause of hospitalizations and proportional mortality, also assuming that most deaths register only the immediate cause of this death, which is often the result of diabetes complications. Most of these complications are cardiovascular diseases, which may manifest as coronary heart disease, cerebrovascular disease or peripheral arteriopathies. These are the so-called macrovascular complications of type 2 diabetes and are present even before the onset of hyperglycemia, due to the presence of insulin resistance and associated metabolic syndrome. Metabolic syndrome is characterized by the presence in the patient of at least 3 out of 5 parameters (increased abdominal waist, high glycemia, hypertriglyceridemia, low HDL-C and arterial hypertension) and is one of the factors responsible for the macrovascular changes.
{"title":"Insulin resistance and its metabolic, lipid and cardiovascular consequences","authors":"T. L. Martinez, Sidney Carvalho Fernandes, A. Saldanha, A. Margeotto, A. Gasparoto, J. Aldrighi, Marco Antonio De Vivo Barros","doi":"10.15406/jccr.2021.14.00508","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00508","url":null,"abstract":"Many research groups on atherosclerosis have sought through prospective large-scale epidemiological studies to better understand which residual factors would be associated with cardiovascular risk. Thus, atherogenic dyslipidemia was defined, such as the presence in an individual of decreased HDL-C levels, increased triglyceride levels, and a relatively high proportion of small and dense LDL-C particles. On the other hand, it was found that atherogenic dyslipidemia is present in cases of insulin resistance and metabolic syndrome (low HDL-C and elevated triglycerides are part of the definition of this syndrome) and consequently in patients with type 2 diabetes mellitus. Regarding treatment, there are studies in diabetic patients with risk reduction with fenofibrate, and the guidelines recommend the association of fenofibrate with statins. Diabetes mellitus is also an important cause of hospitalizations and proportional mortality, also assuming that most deaths register only the immediate cause of this death, which is often the result of diabetes complications. Most of these complications are cardiovascular diseases, which may manifest as coronary heart disease, cerebrovascular disease or peripheral arteriopathies. These are the so-called macrovascular complications of type 2 diabetes and are present even before the onset of hyperglycemia, due to the presence of insulin resistance and associated metabolic syndrome. Metabolic syndrome is characterized by the presence in the patient of at least 3 out of 5 parameters (increased abdominal waist, high glycemia, hypertriglyceridemia, low HDL-C and arterial hypertension) and is one of the factors responsible for the macrovascular changes.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85362204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-22DOI: 10.15406/jccr.2021.14.00506
M. Moran
Introduction: Coronary artery disease (CAD) is the leading cause of early mortality in Western countries. Coronary artery calcium (CAC) is a reliable study to predict future myocardial events and offers independent cardiac risk information. Standard CAD medications, statins, do not reverse CAC. CAD is a chronic disease mainly caused by chronic inflammation. Reversing or partially reversing CAC using a functional approach, without any prescription medications, is theoretically possible due to the chronic inflammatory nature of CAD. Diagnosis: Diagnosis and follow-up of CAC can be easily performed with CT imaging. Interventions: A baseline cardiac scan was performed, and the presence of mild CAC was confirmed in a 60-year-old male. A functional approach, without any prescription medications, was started a few months later and continued for 12 months. A repeat CT scan performed at this time, showed a significant CAC improvement. Conclusion: A twelve-month functional approach, without prescription medications, successfully decreased CAC.
{"title":"Reversing coronary artery calcium using a functional medicine protocol","authors":"M. Moran","doi":"10.15406/jccr.2021.14.00506","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00506","url":null,"abstract":"Introduction: Coronary artery disease (CAD) is the leading cause of early mortality in Western countries. Coronary artery calcium (CAC) is a reliable study to predict future myocardial events and offers independent cardiac risk information. Standard CAD medications, statins, do not reverse CAC. CAD is a chronic disease mainly caused by chronic inflammation. Reversing or partially reversing CAC using a functional approach, without any prescription medications, is theoretically possible due to the chronic inflammatory nature of CAD. Diagnosis: Diagnosis and follow-up of CAC can be easily performed with CT imaging. Interventions: A baseline cardiac scan was performed, and the presence of mild CAC was confirmed in a 60-year-old male. A functional approach, without any prescription medications, was started a few months later and continued for 12 months. A repeat CT scan performed at this time, showed a significant CAC improvement. Conclusion: A twelve-month functional approach, without prescription medications, successfully decreased CAC.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74085815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-25DOI: 10.15406/jccr.2021.14.00501
Mateo Zuluaga Gómez, Diego Fernando Abreo Leal, Andrés Felipe Estrada Atehortúa, Juan Pablo Muñoz Rengifo
Pulmonary thromboembolism is a highly fatal entity, and usually presents atypically. Between 80 and 90% of cases of cardiorespiratory arrest secondary to pulmonary embolism occur between 1 and 3hours after the onset of symptoms, requiring a high degree of clinical suspicion as patient management and prognosis will depend on this. We present the case of a 72-year-old man, admitted after gastrointestinal symptoms and syncope, and who presented cardiorespiratory arrest while in the emergency room. Prior to the circulatory arrest, signs of right ventricular dysfunction and intracavitary thrombi were documented, so systemic thrombolysis was administered overall during resuscitation maneuvers. Subsequently the patient evolved successfully with no cardiac or neurological dysfunction.
{"title":"Intra-arrest thrombolysis in pulmonary thromboembolia with a successful clinical and neurological outcome: a case report","authors":"Mateo Zuluaga Gómez, Diego Fernando Abreo Leal, Andrés Felipe Estrada Atehortúa, Juan Pablo Muñoz Rengifo","doi":"10.15406/jccr.2021.14.00501","DOIUrl":"https://doi.org/10.15406/jccr.2021.14.00501","url":null,"abstract":"Pulmonary thromboembolism is a highly fatal entity, and usually presents atypically. Between 80 and 90% of cases of cardiorespiratory arrest secondary to pulmonary embolism occur between 1 and 3hours after the onset of symptoms, requiring a high degree of clinical suspicion as patient management and prognosis will depend on this. We present the case of a 72-year-old man, admitted after gastrointestinal symptoms and syncope, and who presented cardiorespiratory arrest while in the emergency room. Prior to the circulatory arrest, signs of right ventricular dysfunction and intracavitary thrombi were documented, so systemic thrombolysis was administered overall during resuscitation maneuvers. Subsequently the patient evolved successfully with no cardiac or neurological dysfunction.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80479855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：